Correlation Between Thyroid Function and Quality of Life in Hypothyroidism
1 other identifier
observational
98
1 country
1
Brief Summary
According to the prevalence survey of thyroid diseases in ten cities in China in 2010, TSH\>4.2 mIU /L was the diagnostic cut-off point, and the prevalence of hypothyroidism was 17.8%, including 1.1% clinical hypothyroidism.The annual incidence of hypothyroidism in China is 2.9‰, and primary hypothyroidism is the most common.Typical patients have chilliness, fatigue, swelling of hands and feet, lethargy, memory loss, hypoperspiration, joint pain, weight gain, constipation, menstrual disorder or menorrhagia, infertility, which affects the physiological and psychological functions of patients and reduces the quality of life of patients.The treatment goal of primary clinical hypothyroidism is that the symptoms and signs of hypothyroidism disappear, and TSH, TT4 and FT4 values remain in the normal range.Levothyroxine (L-T4) is the main alternative therapy for this disease.Thyroid disease patients quality of life questionnaire (Thyroid - specific Patient Reported Outcome, ThyPRO) for the development of the Danish scholars such as WATT first can be applied to various comprehensive scale of benign Thyroid disease patients, applied in the Danish people has good reliability and validity, has been translated into ten languages application in many countries the crowd, WATT et al in 2015 developed the scale of the concise version (ThyPRO39).Studies have shown that in the treatment of patients with thyroid disease, even if thyroid function is within the normal range, there are still physiological or psychological impairments such as chills, fatigue, anxiety, depression, which reduces the quality of life of patients.Studies have shown that TSH level in patients with hypothyroidism is correlated with patients' quality of life. Even within the normal range, the higher TSH level is, the worse the patients' quality of life score is, and there is an independent correlation in fatigue and emotional susceptibility. This study except for other factors, such as merger disease with primary hypothyroidism patients quality of life assessment, observe the normal JiaJian patients, we use the current widely used thyroid disease patients to evaluate the quality of life questionnaire (ThyPRO - 39), observe thyroid hormone levels in patients with hypothyroidism and their quality of life scale and the relevance of the blood sugar, blood lipid metabolic indicators related to relevance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2020
CompletedFirst Submitted
Initial submission to the registry
March 10, 2021
CompletedFirst Posted
Study publicly available on registry
March 12, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2021
CompletedMarch 12, 2021
March 1, 2021
1 year
March 10, 2021
March 10, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Thyroid-specific Patient Reported Outcome(ThyPRO39)
Correlation between thyroid function level and health-related quality of life (HRQOL) and metabolic indexes.
1year
Secondary Outcomes (1)
the MOS 36-item Short Form Health Survey(SF36)
baseline
Interventions
There is no intervention in this study
Eligibility Criteria
Patients with hypothyroidism in Chaoyang Hospital outpatient department
You may qualify if:
- Male or female aged ≥18, ≤75 years old;
- clear diagnosis of primary hypothyroidism;
- Use the same dose of levothyroxine for ≥3 months;
- The levels of thyroid function (TSH, TT4, FT4, TT3, FT3) in hospital laboratory blood tests no more than 6 weeks before participation were within the normal range;
You may not qualify if:
- regnancy or lactation women
- affect blood sugar, blood lipid metabolism drugs
- serious heart disease
- thyroid malignant tumor
- history of mental illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
BeijingCYH
Beijing, Beijing Municipality, 100020, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Guang Wang
Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of Endocrinology
Study Record Dates
First Submitted
March 10, 2021
First Posted
March 12, 2021
Study Start
November 1, 2020
Primary Completion
November 1, 2021
Study Completion
November 1, 2021
Last Updated
March 12, 2021
Record last verified: 2021-03